1. Home
  2. CTNM vs BPRN Comparison

CTNM vs BPRN Comparison

Compare CTNM & BPRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • BPRN
  • Stock Information
  • Founded
  • CTNM 2009
  • BPRN 2007
  • Country
  • CTNM United States
  • BPRN United States
  • Employees
  • CTNM N/A
  • BPRN N/A
  • Industry
  • CTNM
  • BPRN Major Banks
  • Sector
  • CTNM
  • BPRN Finance
  • Exchange
  • CTNM Nasdaq
  • BPRN Nasdaq
  • Market Cap
  • CTNM 248.7M
  • BPRN 209.1M
  • IPO Year
  • CTNM 2024
  • BPRN N/A
  • Fundamental
  • Price
  • CTNM $12.40
  • BPRN $32.55
  • Analyst Decision
  • CTNM Strong Buy
  • BPRN Strong Buy
  • Analyst Count
  • CTNM 4
  • BPRN 1
  • Target Price
  • CTNM $22.75
  • BPRN $35.00
  • AVG Volume (30 Days)
  • CTNM 246.0K
  • BPRN 7.2K
  • Earning Date
  • CTNM 11-05-2025
  • BPRN 10-28-2025
  • Dividend Yield
  • CTNM N/A
  • BPRN 3.71%
  • EPS Growth
  • CTNM N/A
  • BPRN N/A
  • EPS
  • CTNM N/A
  • BPRN 1.00
  • Revenue
  • CTNM N/A
  • BPRN $68,942,000.00
  • Revenue This Year
  • CTNM N/A
  • BPRN $13.82
  • Revenue Next Year
  • CTNM N/A
  • BPRN $15.85
  • P/E Ratio
  • CTNM N/A
  • BPRN $32.41
  • Revenue Growth
  • CTNM N/A
  • BPRN N/A
  • 52 Week Low
  • CTNM $3.35
  • BPRN $27.25
  • 52 Week High
  • CTNM $20.30
  • BPRN $39.35
  • Technical
  • Relative Strength Index (RSI)
  • CTNM 69.65
  • BPRN 49.34
  • Support Level
  • CTNM $11.46
  • BPRN $31.75
  • Resistance Level
  • CTNM $13.09
  • BPRN $33.28
  • Average True Range (ATR)
  • CTNM 1.02
  • BPRN 0.60
  • MACD
  • CTNM -0.07
  • BPRN -0.16
  • Stochastic Oscillator
  • CTNM 74.89
  • BPRN 22.54

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

About BPRN Princeton Bancorp Inc. (PA)

Princeton Bancorp Inc is a banking company. It is a full-service financial institution that provides business and personal banking. Its personal banking and business banking services include checking accounts and savings accounts. It offers traditional retail banking services, one-to-four-family residential mortgage loans, multi-family and commercial mortgage loans, construction loans, commercial business loans, and consumer loans, including home equity loans and lines of credit. The Bank also has two retail branches and conducts loan origination activities in select areas of the New York City metropolitan area.

Share on Social Networks: